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Abstract 
We have assessed the efficacy of anti retroviral therapy (ART) using undetectable viral load (VL) 
(<50 RNA copies/ml) as a marker of virological success, in patients who have Human 
Immunodeficiency Virus (HIV) attending the Department of Infectious Disease. A cross-sectional 
review of patients’ case notes was used to obtain their demographics and treatment details. 79% 
(253) of the hospital case notes of clinic population was available for analysis, which represents 90% 
of those receiving ART in the clinic. 166/253 of the cohort were receiving treatment at the time of this 
study and 95% (157/166) of these were on treatment for greater than 6 months. The total virological 
success rate is 93%, which is comparable to other centres and are as good as those from published 
clinical trials. 56% of those on therapy who have virological failure were Intravenous Drug Users 
(IVDUs). Case by case investigation for those with treatment failure is warranted.  
 
Introduction 
Despite advances in the pharmacology of anti retroviral therapy (ART), how they are utilised varies 
widely and thus measured outcomes can be diverse1. The role of a clinical audit is to evaluate and 
compare results with standard accepted practice and to highlight any shortcomings and areas that 
may be improved (National Institute of Clinical Excellence 2002). As a review of our quality of care 
we have assessed our use of ART using undetectable viral load (VL) (<50 RNA copies/ml) as a 
marker of virological success. The results of this audit can therefore be used to highlight current 
shortcomings in practice, to guide future practice and to encourage further research. 
 
Methods 
All (Human Immunodeficiency Virus) HIV positive patients attending the infectious disease clinic were 
identified from a card index file. A cross-sectional chart review was carried out recording their 
variables in a data base. Patients who have passed away or are currently being followed up by other 
centres were excluded from this audit. The data was obtained directly from each patient’s hospital 
case notes, which included patients’ demographics (Table 1) and their treatment details, VL in last 4 
visits, latest CD4 counts, current and past ART regimens details. 
Success of treatment was defined as patients with a VL < 50 copies/ml at the point of last 
measurement of HIV VL. Prevalence of viral load suppression < 50 copies/ml was recorded from the 
most recent clinic attendance. Those on treatment with a viral load >50-<400 copies/ml had their 
previous 3 viral loads also recorded to identify recent patterns to differentiate between viral load blips, 
declining viral loads and true virological failure. Sub-analysis was conducted on different groups as 
outlined below; (a) Treatment naïve patients i.e. patients that have never been on antiretroviral 
therapy. (b) Patients that are currently off treatment but who were on treatment in the past, i.e. the 
‘On Off treatment’ group. (c) Patients that started therapy for the first time less than six months   ago 
i.e. < 6 months on treatment.(d) Patients that have been on therapy for greater than six months i.e. > 
6 months on treatment. 
 
Results 
Seventy nine percent (253/320) of the population had hospital case notes available for analysis. This 
captured 90% of those who are on ART (166/185). 
 
General clinic demographics (Table 1) 
The general demographics of the HIV clinic reveal a fairly equal gender divide with 49% men and 
51% women. Diversity is reflected by the 29 different Nationalities attending the clinic. Patients were 
divided into those from Africa (50%, of which the biggest group, 28% are Nigerian) and those from 
Europe (49%, 89% of these are Irish) with a very small minority (1%) from Asia. The majority of 
patients are between 30 and 50 years of age (74%). The most likely mode of transmission was the 
heterosexual route - 56%. However only 39% of the European population cited the heterosexual 
route compared with 79% of the the African population. The other main transmission routes in the 
European population were intravenous drug use (IVDU) 26% and men who have sex with men 
(MSM) 22%. The average time since first diagnosis of HIV was 5.5 yrs. In relation to the Irish 
population 65% were male and most were between the ages of 40-49 years (45%). The most likely 
mode of transmission was heterosexual (41%). Most of the patients within the Irish heterosexual 
category were female (58%).  
 
Treatment Naïve Group 
58/87 of the patients off therapy were treatment naive. An average person in the treatment naïve 
group would be an African Hetrosexual male between the ages of =19-29 years who has recently 
been diagnosed. The CD4 counts in the treatment naïve group demonstrated that 68% of this group 
have CD4 counts greater than 350/µL and therefore treatment is not warranted. However 29% in this 
group have CD4 counts between 200-350/µL and these patients should be closely monitored so that 
treatment is initiated before advanced immuno-suppression occurs. Indeed these patients are 
recalled for monthly check-ups to the clinic. Significantly there were no patients in the treatment 
naïve group that had CD4 counts less than 200/µL (Table 2). 
On-Off Treatment Group 
In the on-off treatment group (29 patients) there was a much higher percentage of African, female 
gender, and the age group below 40 years. 65% of the patients in this group were receiving ART 
medication during pregnancy to prevent mother to child transmission and medication was stopped 
postpartum. In the on-off treatment group 62% of patients had CD4 counts >350/µL and so treatment 
was not required. 17% in this group have CD4 counts between 200-349/µL and these patients must 
be monitored closely. 21% (6 patients) have CD4 levels less than 200/µL. According to accepted 
guidelines these patients should be on treatment. A third of these patients is intravenous drug users 
and has poor compliance recorded in their charts. The remaining scenarios were equally divided 
between, postpartum, drug resistance, patient preference to stop medication and one for unknown 
reasons (Table 3).  
 
<6 months of Tx 
The average person in this group is an African hetrosexual male between the ages of 20 and 30. 
There were 9 patients audited who had started treatment in the last 6 months. Of these, one patient 
achieved virological suppression with a viral load of less than 50 copies/mL. It is difficult to interpret 
this data accurately as many of the patients in this group had only started their regimens some weeks 
ago. A longer follow up period is required to accurately assess their viral loads. 
 
>6 months of Tx 
An average person in this group is a European heterosexual man greater than 40 years of age. 
There were 157 patients on treatment for greater than 6 months (Table 4). Virological success was 
achieved in 83% of cases. 15/16 patients with viral loads between >50-<400 copies/ml, had either 
declining viral loads or a once off blip in results that on follow up would be expected to reach viral 
suppression. Thus the overall rate of virological success can be taken as 93%. One patient in this 
group was in true virological failure where the previous 3 viral loads reflected a consistent increase in 
the viral load levels. 
33 patients were taking the LTAR regimen (Lamivudine/Tenovofir/Atazanavir /Ritonavir). There are 
34 other different regimens in use in the clinic. Nine of the patients that were on treatment had viral 
loads of >1,000 copies/ml, treatment has failed in these cases. Five of these were intravenous drug 
users and with poor compliance recorded. Mode of transmission for one of these patients was the 
vertically acquired route and drug resistance may have been a factor here. 
 
Discussion 
One of the findings of this audit is the demographical differences between the European and African 
populations. The European patients are generally older and constitute the majority in the ‘treatment 
for more than six months’ category. The older European population may be due to successful 
treatment regimens and effective public health HIV prevention campaigns. In Ireland regarding future 
HIV prevention campaigns it is worth noting that the majority (41%) of the Irish population acquired 
HIV by the heterosexual route. The African population are generally younger and predominate in the 
‘treatment naïve’ and in the ‘<6 months Tx’ categories. This may be explained by the earlier detection 
rates in the African population as part of current refugee screening policies so that the African 
population may be over represented.   
The fact that none of the patients in the ‘treatment naïve’ category had CD4 count <200/µL reflects 
the efficiency of the clinic in identifying patients that require treatment. It is only within the ‘on-off 
treatment’ category that CD4 counts <200/µL exist. In this group, treatment was offered to patients 
and for reasons such as poor compliance, patient preference, and the development of resistance 
these patients are not currently on medication. Our total virological success rate of 93% compares 
favourably with similar published audit results (Curtis et al 20032 - 58.9% had VL<50copies/ml, 
Madge et al 20083 - 92% had VL<50copies/ml). 
The use of 35 different regimens in the clinic reflects how essential it is to tailor therapy to the 
individual’s needs. This would have contributed greatly to our high virological success rate. With 
33/166 patients receiving the LTAR 1st line regimen, further analysis may be useful in comparing this 
with other regimens used in other clinics. Over half of those with virological failure despite being on 
treatment for greater than six months, reported ‘IVDU’ as the mode of transmission. Poor compliance 
was recorded in these cases. Despite a multidisciplinary approach to care in the HIV clinic perhaps 
an early more targeted holistic approach for this subset of patients would be beneficial such as the 
inclusion of specialist addiction counsellors. A further case by case investigation for those with 
treatment failure is warranted and their eligibility for alternative classes of ART e.g. fusion 
inhibitors4 should be considered. 
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